Capture Yield In Th...
Health Care: Drugs
Biogen Idec Inc (BIIB: NASDAQ)
$121.88 0.62 | 0.51%
02/03/12 - 04:00 PM ET
1.20M / 1.63M
Vol / Avg. Vol:122.24 / 121.26
Open / Prev. Close:121.06 - 122.78
Today's Range:64.61 - 123.23
52 Wk Range:10.75%
Performance YTD:TheStreet Rating:
Portfolios with BIIB
- Portfolio NameUser Type
- Contributor10 Health Care Stocks to Watch
- UserNarf's stocks
- ContributorTop-Rated Biotechnology Stocks
- Contributor10 Best-Performing S&P 500 ...
- Contributor10 Best-Performing S&P 500 ...
- ProGeorge Soros
- ProViking Global Investors
- ProBruce Kovner - Caxton Assoc...
- UserCramer - Rates - A/B
- Contributor8 Biotech Stocks to Watch
Latest BIIB Headlines from TheStreet
- 3 Stocks I Saw on TV, February 3
02.03.12 | 07:02 am - 9 Stocks Hitting 52-Week Highs: MSFT, TJX, BEAV, BIIB, CA, WRB, PVX, MMC, OII 02.01.12 | 05:02 pm
- Biogen Idec Stock Hits New 52-Week High (BIIB) 02.01.12 | 11:02 am
- Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript 01.31.12 | 01:01 pm
- Biogen's 2012 Forecast Disappoints 01.31.12 | 07:01 am
- 3 Stocks I Saw on TV, January 30 01.30.12 | 07:01 am
- The Week Ahead: Investors Eye Jobs Data, Earnings 01.29.12 | 04:01 pm
- 10 Health Care Stocks to Watch 01.27.12 | 05:01 pm
- 3 Stocks I Saw on TV, January 27 01.27.12 | 08:01 am
- Live in a Super Bowl City 01.27.12 | 07:01 am
Press Releases for BIIB
- Biogen Idec Surpasses $5 Billion In 2011 Annual Revenue - Business Wire 01.31.12 | 07:01 am
- Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources - Business Wire 01.30.12 | 08:01 am
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
- Biogen Idec To Report Fourth Quarter & Year End 2011 Financial Results On January 31, 2012 - Business Wire 01.13.12 | 04:01 pm
- Biogen Idec Presents 2012 Strategic Priorities At 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.09.12 | 09:01 am
- Biogen Idec And Isis Pharmaceuticals Announce Global Collaboration For Antisense Program Targeting Spinal Muscular Atrophy - Business Wire 01.04.12 | 08:01 am
- Biogen Idec To Present At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.03.12 | 04:01 pm
- Biogen Idec To Present At The Goldman Sachs Healthcare CEOs Unscripted Conference - Business Wire 12.28.11 | 04:12 pm
- ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate The Role Of CD40L In ALS - PR Newswire 12.19.11 | 09:12 am
Partner Headlines for BIIB
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
- Label Expansion for Merck KGaA Drug - Analyst Blog - Zacks 01.27.12 | 04:01 pm
- Label Expansion for Merck KGaA Drug - Analyst Blog - Zacks 01.27.12 | 04:01 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases - Zacks 01.26.12 | 09:01 am
- Oppenheimer Releases Biogen Idec Company Update - Benzinga 01.23.12 | 09:01 am
- Neutral on Biogen - Analyst Blog - Zacks 01.20.12 | 05:01 pm
- Keeping An Eye On Isis - Seeking Alpha 01.13.12 | 07:01 pm
- Biosimilars: The Next Big Thing - Analyst Blog - Zacks 01.13.12 | 05:01 pm
- Biotech Stocks On A Tear: I Like Celgene - Seeking Alpha 01.13.12 | 09:01 am
